{"classes":[{"categories":[{"measurements":[{"comment":"Geometric mean and geometric coefficient of variation were not reported for n \\< 3.","groupId":"OG000","spread":"NA","value":"NA"},{"comment":"Geometric mean and geometric coefficient of variation were not reported for n \\< 3.","groupId":"OG001","spread":"NA","value":"NA"},{"comment":"Geometric mean and geometric coefficient of variation were not reported for n \\< 3.","groupId":"OG002","spread":"NA","value":"NA"},{"groupId":"OG003","spread":"12","value":"2.360"},{"groupId":"OG004","spread":"31","value":"2.073"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"4"},{"groupId":"OG004","value":"3"}],"units":"Participants"}],"description":"Rac was calculated by (Cycle 4 AUCtau) / (Cycle 1 AUCtau). AUCtau was Area under the serum concentration time profile from time zero to time tau, the dosing interval, where tau = 504 hours for Q3W IV dosing and tau = 672 hours for every 4 weeks (Q4W) SC dosing.","dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Participants received PF-06801591 0.5 mg/kg IV every 3 weeks for 21-day cycles. (maximum of 1186 days)","id":"OG000","title":"Part 1: PF-06801591 0.5 mg/kg (Intravenously [IV])"},{"description":"Participants received PF-06801591 1 mg/kg IV every 3 weeks for 21-day cycles. (maximum of 659 days)","id":"OG001","title":"Part 1: PF-06801591 1 mg/kg (IV)"},{"description":"Participants received PF-06801591 3 mg/kg IV every 3 weeks for 21-day cycles. (maximum of 1606 days)","id":"OG002","title":"Part 1: PF-06801591 3 mg/kg (IV)"},{"description":"Participants received PF-06801591 10 mg/kg IV every 3 weeks for 21-day cycles. (maximum of 445 days)","id":"OG003","title":"Part 1: PF-06801591 10 mg/kg (IV)"},{"description":"Participants received PF-06801591 300 mg SC every 4 weeks for 28-day cycles. (maximum of 419 days)","id":"OG004","title":"Part 1: PF-06801591 300 mg (Subcutaneously [SC])"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"Analysis population included all enrolled participants treated who were evaluable for this outcome measure.","reportingStatus":"POSTED","timeFrame":"Pre-dose and 1 hour post dose on Day 1 of Cycles 1 and 4 in Part 1","title":"Accumulation Ratio (Rac) of PF-06801591 - Part 1","type":"SECONDARY","unitOfMeasure":"Ratio"}